Supernus Announces Issuance of Seventh U.S. Patent Protecting Trokendi XR®
January 30 2017 - 7:00AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty
pharmaceutical company focused on developing and commercializing
products for the treatment of central nervous system diseases,
today announced the issuance on January 24, 2017 of a seventh
patent (number 9,549,940) by the United States Patent and Trademark
Office (USPTO) covering Trokendi XR®, its novel once-daily
extended-release topiramate product. The patent provides protection
for the product with expiration that is no earlier than 2027.
“This patent is an important addition to our overall
intellectual property patent portfolio. We now have patent
protection on Trokendi XR and Oxtellar XR® through seven issued
U.S. patents each, and we remain focused on continuing to
expand our patent coverage to provide our products with the
protection they deserve,” said Jack A. Khattar, President and CEO
of Supernus.
Supernus has several additional patent applications for
extended-release oxcarbazepine and extended-release topiramate
pending in other geographic regions.
About Trokendi XR
Trokendi XR is the first approved novel once-daily extended
release formulation of topiramate for the treatment of epilepsy.
Trokendi XR is an antiepileptic drug indicated for initial
monotherapy in patients 6 years of age and older with partial onset
or primary generalized tonic-clonic seizures; adjunctive therapy in
patients 6 years of age and older with partial onset or primary
generalized tonic-clonic seizures; and adjunctive therapy in
patients 6 years of age and older with seizures associated with
Lennox-Gastaut syndrome. The product is available in 25mg, 50mg,
100mg and 200mg extended-release capsules.
For current full prescribing and safety information, click
here
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical
company focused on developing and commercializing products for the
treatment of central nervous system diseases. The Company has two
marketed products for epilepsy, Oxtellar XR® (extended-release
oxcarbazepine) and Trokendi XR® (extended-release topiramate). The
Company is also developing several product candidates to address
large market opportunities in psychiatry, including SPN-810 for the
treatment of Impulsive Aggression in ADHD patients and SPN-812 for
the treatment of ADHD.
Forward Looking Statements
This press release contains forward-looking statements regarding
the Company's ability to defend and enforce its intellectual
property rights covering Oxtellar XR or Trokendi XR. Actual results
may differ materially from those in these forward-looking
statements as a result of various factors, including, but not
limited to, the ability of Supernus to finance potential litigation
and to prevail in any such proceeding to successfully defend its
intellectual property rights. For a further description of these
and other risks facing the Company, please see the risk factors
described in the Company's Annual Report Form 10-KA that was filed
with the United States Securities and Exchange Commission
("Commission") on January 20, 2017 under the caption "Risk Factors"
and the updates to these risk factors in the Company's Quarterly
Report form 10-QA filed with the Commission on January 23, 2017.
Forward-looking statements speak only as of the date of this press
release, and the Company undertakes no obligation to update or
revise these statements, except as may be required by law.
CONTACT:
Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Or
Investor Contact:
Peter Vozzo
Westwicke Partners
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Supernus Pharmaceuticals (NASDAQ:SUPN)
Historical Stock Chart
From Apr 2023 to Apr 2024